NeoDx Biotech Labs, a Bengaluru-based startup at the forefront of innovative diagnostics, has introduced the PML-RARA Qualitative Real-Time PCR Kit and PML-RARA Quantitative Real-Time PCR Kit for the accurate and rapid detection of the PML-RARA fusion gene in Acute Promyelocytic Leukemia (APL). A remarkable feature of NeoDx's kits is their single-tube assay, eliminating the need for additional cDNA steps during reverse transcription.
Cancer is caused due to changes in the genes, which mainly affect cell growth and division. A reciprocal translocation between Chromosome 15 and Chromosome 17, expressed as t(15;17) causes Acute Polymyeloid leukemia, a type of acute myeloid leukemia (AML).
NeoDx’s PML RARA Qualitative and Quantitative kits include TaqMan probes for specific detection of PML-RARA transcripts, alongside an internal control targeting the ABL1 gene, ensuring the robustness of the assay. These One-step RT-PCR multiplex assays are specifically designed to detect PML-RARA transcripts in human EDTA whole blood or bone marrow aspirates, providing invaluable insights for diagnosing APL.
NeoDx also offers various oncology panels in RT-PCR format, in single-tube multiplex formats, including BCR-ABL, JAK2 V617F, and KRAS, amongst others.
NeoDx Biotech Labs envisions that this groundbreaking Real-time PCR Kit will significantly contribute to the early diagnosis and effective management of APL, empowering healthcare professionals to make informed treatment decisions and ultimately improving patient outcomes.
